If you were implanted with a Bard PowerPort device and it fractured, migrated, or caused an infection or blood clot, you may qualify for compensation.
The Bard PowerPort is an implantable catheter port used to deliver chemotherapy, medication, and IV fluids directly into a patient's bloodstream without repeated needle sticks. Lawsuits allege the device's catheter, made from a material called Chronoflex AL, is prone to fracturing, cracking, or migrating inside the body — a failure that can require emergency surgery to retrieve broken fragments and has been linked to infections, blood clots, and injury to the heart or blood vessels.
More than 3,564 of these lawsuits are consolidated in a federal MDL, In re: Bard PowerPort Products Liability Litigation (MDL No. 3081), before Judge David G. Campbell in the District of Arizona. The litigation's second bellwether trial — a fracture case that survived summary judgment — is scheduled for August 18, 2026, with additional bellwether trials set for October 2026, December 2026, and February 2027.
Here's what happens after you reach out:
A short set of free eligibility questions about your situation — takes about two minutes.
Our network reviews your answers against current qualifying criteria and reaches out if you may qualify.
You decide whether to move forward. There's never a cost to check your eligibility.
Filing deadlines vary by state and depend on when your complications were discovered. With bellwether trials now underway and more scheduled through early 2027, it's worth checking with an attorney about your specific timeline sooner rather than later.
A catheter-fracture case survived summary judgment on July 27, 2026 and is set to become the second Bard PowerPort MDL bellwether trial, beginning August 18, 2026, after the first trial ended in a split verdict.
Read more →Get updates on Bard PowerPort, plus other case types we cover.
We'll keep you updated on Bard PowerPort and other case types.